

Substitute for form 1449A/PTO

MAY 14 2002

ATTORNEY'S DKT No.  
032775-091APPLICATION NO.  
10/076,074APPLICANT  
Coffey et al.FILING DATE  
February 15, 2002GROUP  
1642INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTRECEIVED  
MAY 15 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
B&C	6,136,307		Lee et al.	10-24-2000
B&C	6,100,243		Frisch	08-08-2000

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
B&C	WO 94/18992		PCT	09-01-1994		
B&C	WO 94/25627		PCT	11-10-1994		
B&C	WO 99/18799		PCT	04-22-1999		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
B&C	Andreansky, S.A., et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors", <i>Proc. Natl. Acad. Sci.</i> 93(21):11313-11318 (1996).
	Bar-Eli, N., et al., "Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells", <i>J. Cancer Res. Clin. Oncol.</i> 122: 409-415 (1996).
	Bergmann, M., et al., "A Genetically Engineered Influenza A Virus with ras-Dependent Oncolytic Properties", <i>Cancer Res.</i> 61:8188-8193 (2001).
	Bischoff JR. et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells", <i>Science</i> 274(5286):373-6 (1996).
	Blagodatsonny, M.V., et al., "in vitro Evaluation of a p53-Expressing Adenovirus as an Anti-Cancer Drug", <i>Int. J. Cancer</i> 67(3):386-392 (1996).
	Borst et al., "A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins", <i>J. Natl. Cancer Inst.</i> 92(16): 1295-1302 (2000).
	Chandran and Nibert, "Protease Cleavage of Reovirus Capsid Protein $\mu 1/\mu 1C$ is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirus Particle", <i>J. of Virology</i> 72(1):467-75 (1998).
	Chang et al., "Rescue of Vaccinia Virus Lacking the E3L Gene by Mutants of E3L", <i>J. Virol.</i> 69:6605-6608 (1995).
	Chang et al., "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase", <i>Proc. Natl. Acad. Sci.</i> 89:4825-4829 (1992).
	Chang et al., "Identification of a Conserved Motif that is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA", <i>Virol.</i> 194:537-547 (1993).
	Coffey, M.C., et al., "Reovirus Therapy of Tumors with Activated Ras Pathway", <i>Science</i> 282: 1332-1334 (1998).
	DeVita, Jr., "The Relationship Between Tumor Mass and Resistance to Chemotherapy. Implications for Surgical Adjuvant Treatment of Cancer", <i>Cancer</i> 51:1209-1220 (1983).
	Duncan et al., "Conformational and Functional Analysis of the C-Terminal Globular Head of the Reovirus Cell Attachment Protein", <i>Virology</i> 182(2):810-9 (1991).
	Farassati, F., et al., "Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1", <i>Nat. Cell Biol.</i> 3(8):745-750 (2001).
	Fueyo, J., et al., "A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect <i>In Vivo</i> ", <i>Oncogene</i> 19(1):2-12 (2000).
✓	Grant et al., "Overexpression of Multidrug Resistance-Associated Protein (MRP) Increases Resistance to Natural Product Drugs", <i>Cancer Res.</i> 54: 357-361 (1994).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

MAY 14 2002

SHEET 2 OF 2

Substitute for form 1449A/PTO	ATTORNEY's DKT No. 032775-091	APPLICATION NO 10/076,074
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
FILING DATE February 15, 2002	GROUP 1642	RECEIVED FEB 15 2002

RECEIVED  
MAY 15 2004

MAY 15 2002

~~MAY 15 2002~~ 6007290  
TECH CENTER

## **U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
B.O.L.	Heise, C. et al., "Replication-selective adenoviruses as oncolytic agents", <i>J. Clin. Invest.</i> 105(7):847-51 (2000).
	Kawagishi-Kobayashi, M. et al., "Regulation of the Protein Kinase PKR by the Vaccinia Virus Pseudosubstrate Inhibitor K3L is Dependent on Residues Conserved between the K3L Protein and the PKR Substrate eIF2α", <i>Mol. Cell. Biol.</i> 17:4146-4158 (1997).
	Khuri, et al., "A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer", <i>Nat Med</i> 6(8):862-3 (2000).
	Mah et al., "The N-Terminal Quarter of Reovirus Cell Attachment Protein α1 Possesses Intrinsic Virion-Anchoring Function", <i>Virology</i> 179(1):95-103 (1990).
	Nemunaitis, J., "Oncolytic viruses", <i>Invest. New Drugs</i> 17:375-386 (1999).
	Pastan and Gottesman, "Multidrug Resistance", <i>Annu. Rev. Med.</i> 42: 277-286 (1991).
	Reichard, K.W., et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", <i>J. of Surgical Research</i> 52:448-453 (1992).
	Romano et al., "Inhibition of Double-Stranded RNA-Dependent Protein Kinase PKR by Vaccinia Virus E3: Role of Complex Formation and the E3 N-Terminal Domain", <i>Mol. Cell. Bio.</i> 18(12):7304-7316 (1998).
	Sharp et al., "The Vaccinia Virus E3L Gene Product Interacts with both the Regulatory and the Substrate Binding Regions of PKR: Implications for PKR Autoregulation", <i>Virology</i> 250:302-315 (1998).
	Smith, R.E., et al., "Polypeptide Components of Virions, Top Component and Cores of Reovirus Type 3", <i>Virology</i> , 39:791-800 (1969).
	Stojdl, D.F., et al., "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus", <i>Nat. Med.</i> 6(7):821-825 (2000).
	Strong, J.E., et al., "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", <i>EMBO J.</i> 17: 3351-3362 (1998).
	Turner and Duncan, "Site-Directed Mutagenesis of the C-terminal Portion of Reovirus Protein α1: Evidence for a Conformation-Dependent Receptor Binding Domain", <i>Virology</i> 186(1):219-27 (1992).
	Yoon, S.S., et al., "An oncolytic herpes simplex virus type I selectively destroys diffuse liver metastases from colon carcinoma", <i>FASEB J.</i> 14:301-311(2000).
✓	Zorn, U. et al., "Induction of Cytokines and Cytotoxicity against Tumor Cells by Newcastle Disease Virus", <i>Cancer Biotherapy</i> 9(3):22-235 (1994).
Examiner Signature	Baogunki:
	Date Considered
	05/14/2004

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 032775-091	APPLICATION NO. 10/076,074
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	APPLICANT Coffey et al.	FILING DATE February 15, 2002
		GROUP 1642

APR 3 0 2003

U.S. PATENT DOCUMENTS						
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)		
	Number	Kind Code (if known)				
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
BCL	WO 00/50051	A2	PCT	08-31-2000	X	
130C	WO 96/07322	A1	PCT	03-14-1996	X	
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
BCL	Fujiwara, T., et al., Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type p53 Gene <sup>1</sup> , <i>Cancer Research</i> 54:2298-2291 (1994).					
↓	Heise, C., et al., Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration, <i>Clinical Cancer Research</i> 6:4908-4914 (2000).					
✓	Kirn, D., Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer, <i>Oncogene</i> 19:6660-6669 (2000).					
RECEIVED						
MAY 05 2003						
TECH CENTER 1600/2900						
Examiner Signature	Baogen Li		Date Considered	05/11/04		

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SFND TO: Assistant Commissioner for Parents, Washington, D.C. 20231.